UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Britain Courts Anthropic Amid US Defense Department Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MENLO PARK, Calif., July 25, 2017 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report its second quarter 2017 financial results and provide a corporate update on August 1, 2017. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 45276605.
A replay will be available through August 15, 2017 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode will be 45276605.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company’s first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT: Charles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 [email protected] www.corcept.com
